COVID-19 and emerging viral infections: The case for interferon lambda

Author:

Prokunina-Olsson Ludmila1ORCID,Alphonse Noémie23ORCID,Dickenson Ruth E.2,Durbin Joan E.45,Glenn Jeffrey S.6,Hartmann Rune7ORCID,Kotenko Sergei V.589,Lazear Helen M.10ORCID,O’Brien Thomas R.11,Odendall Charlotte2,Onabajo Olusegun O.1,Piontkivska Helen12ORCID,Santer Deanna M.13ORCID,Reich Nancy C.14,Wack Andreas3,Zanoni Ivan15ORCID

Affiliation:

1. Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

2. Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK

3. Immunoregulation Laboratory, Francis Crick Institute, London, UK

4. Department of Pathology, Laboratory Medicine and Immunology, Newark, NJ

5. Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ

6. Departments of Medicine and Microbiology & Immunology, Stanford University School of Medicine, and Palo Alto Veterans Administration, Palo Alto, CA

7. Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark

8. Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ

9. Center for Cell Signaling, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ

10. Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC

11. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

12. Department of Biological Sciences, School of Biomedical Sciences, Kent State University, Kent, PA

13. Li Ka Shing Institute of Virology and Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada

14. Department of Microbiology & Immunology, Stony Brook University, Stony Brook, NY

15. Division of Immunology, Division of Gastroenterology, Harvard Medical School, Boston Children’s Hospital, Boston, MA

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Funder

National Cancer Institute

National Institutes of Health

Kent State University

Royal Society

Wellcome Trust

Francis Crick Institute

Cancer Research UK

UK Medical Research Council

King’s College London

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

Cited by 177 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3